Table 2.

Summarized outcomes of trials assessing treatment regimens in patients with AF with ACS or PCI/stenting 25

Outcomes	VKA + DAPT (reference)
	VKA + P2Y12 inhibitor		DOAC + DAPT		DOAC + P2Y12 inhibitor
	HR	95% CI	HR	95% CI	HR	95% CI
TIMI major bleeding	0.58	0.31‐1.08	0.70	0.38‐1.23	0.49	0.30‐0.82
TIMI major and minor bleeding	0.49	0.26‐0.92	0.63	0.33‐1.17	0.43	0.25‐0.76
Primary safety outcome (trial defined)	0.45	0.21‐0.92	0.64	0.31‐1.31	0.47	0.25‐0.85
ICH	1.44	0.40‐5.22	0.54	0.15‐1.92	0.26	0.08‐0.79
All‐cause death	0.84	0.40‐1.56	1.04	0.54‐1.98	1.02	0.59‐1.74
Cardiovascular death	0.82	0.42‐1.49	0.94	0.53‐1.63	1.11	0.70‐1.75
Primary MACE (trial defined)	0.96	0.60‐1.46	0.94	0.60‐1.15	1.02	0.71‐1.97
MI	1.25	0.77‐1.99	1.13	0.72‐1.78	1.18	0.81‐1.72
Stroke	1.02	0.36‐2.65	0.91	0.35‐2.32	0.77	0.34‐1.67
Stent thrombosis	1.08	0.46‐2.31	0.93	0.40‐2.17	1.41	0.71‐2.76
Hospitalization	0.86	0.57‐1.23	0.80	0.55‐1.13	0.80	0.59‐1.08

Odds ratio < 1 favors nonreference strategy; odds ratio > 1 favors reference strategy.

Abbreviations: CI, confidence interval; DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulants; ICH, intracranial hemorrhage; MACE, major adverse cardiac event; MI, myocardial infarction; OR, odds ratio; TIMI, Thrombolysis in Myocardial Infarction; VKA, vitamin K antagonist.